Free account + included starter software — credential review typically takes 1–2 business days. See how it works
PHENYLEPHRINE OPTH SOL 2.5% 15ML - 25 mg/mL SOLUTION/ DROPS
Request Item

PHENYLEPHRINE OPTH SOL 2.5% 15ML

Generic: Phenylephrine Hydrochloride

PHENYLEPHRINE OPTH SOL 2.5% 15ML

NDC:70756-0649-35
Manufacturer:Lifestar Pharma LLC
Strength:25 mg/mL
Dosage Form:SOLUTION/ DROPS
Route:OPHTHALMIC

Sign up to see pricing

Licensed pharmacies, clinics, doctor's offices, and veterinary practices get instant account approval

Sign Up — Instant Approval

Drug Information

Identification

Generic Name

Phenylephrine Hydrochloride

Brand Name

Phenylephrine Hydrochloride

Labeler / Distributor

Lifestar Pharma LLC

Product Type

HUMAN PRESCRIPTION DRUG

Administration

Dosage Form

SOLUTION/ DROPS

Route of Administration

OPHTHALMIC

FDA Application Number

ANDA216859

Active Ingredients

IngredientStrength
PHENYLEPHRINE HYDROCHLORIDE25 mg/mL

Pharmacological Class

Adrenergic alpha1-Agonists [MoA]alpha-1 Adrenergic Agonist

Data sourced from openFDA / DailyMed. For full prescribing information, consult the drug label.

Clinical Drug Information

Indications & Usage

1 INDICATIONS AND USAGE Phenylephrine Hydrochloride Ophthalmic Solution 2.5% and 10%, is indicated to dilate the pupil. Phenylephrine Hydrochloride Ophthalmic Solution is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil ( 1 )

Dosage & Administration

2 DOSAGE AND ADMINISTRATION For patients 1 year of age and older : ( 2.1 ) Apply one drop of Phenylephrine Hydrochloride Ophthalmic Solution (2.5% and 10% strength) to conjunctival fornix at 3 to 5 minute intervals up to a maximum of 3 drops per eye. To obtain a greater degree of mydriasis, use 10% strength For pediatric patients less than 1 year of age : ( 2.2 ) Instill one drop of 2.5% strength to conjunctival fornix at 3 to 5 minute intervals up to a maximum of 3 drops per eye 2.1 General Dosing Recommendations In patients 1 year of age or greater, apply one drop of phenylephrine hydrochloride ophthalmic solution 2.5% or 10% every 3 to 5 minutes to the conjunctival fornix as required up to a maximum of 3 drops per eye per day. In order to obtain a greater degree of mydriasis, phenylephrine hydrochloride ophthalmic solution 10% may be needed. 2.2 Dosing in Pediatric Patients Less Than 1 Year of Age In pediatric patients less than 1 year of age, one drop of phenylephrine hydrochloride ophthalmic solution 2.5% should be instilled at 3 to 5 minute intervals up to a maximum of 3 drops per eye.

Adverse Reactions

6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Cardiovascular Effects [ See Warnings and Precautions ( 5.2 )] Elevation in Blood Pressure [ See Warnings and Precautions ( 5.3 )] The following adverse reactions have been identified following use of phenylephrine hydrochloride ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. To report SUSPECTED ADVERSE REACTIONS, contact Lifestar Pharma LLC at 1-888-995-4337 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision, and photophobia ( 6.1 ) Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage ( 6.2 ) 6.1 Ocular Adverse Reactions Eye pain and stinging on instillation, temporary blurred vision and photophobia, and conjunctival sensitization may occur. 6.2 Systemic Adverse Reactions A marked increase in blood pressure has been reported particularly, but not limited to low weight premature neonates, infants and hypertensive patients. Cardiovascular effects which have been seen primarily in hypertensive patients following topical ocular use of phenylephrine hydrochloride ophthalmic solution 10% include marked increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage [ See Warnings and Precautions ( 5.2 and 5.3 )].

Information for Patients

17 PATIENT COUNSELING INFORMATION Advise patients not to touch the dropper tip to any surface as this may contaminate the solution. Inform patients that they may experience sensitivity to light and should protect their eyes in bright illumination while their pupils are dilated. Manufactured for: Lifestar Pharma LLC 1200 MacArthur Blvd. Mahwah, NJ 07430 USA Made in India Revised: : July 2025, V-05

Clinical data sourced from openFDA drug labeling. For complete prescribing information, consult the full drug label.